FORMS OF PROSTATE SPECIFIC ANTIGEN AND HK2 IN CANCER

$0M01FY2000RRNIH

Scripps Research Institute, La Jolla CA

Investigators

Linked publications & trials

Paper 21743843 Paper 20729202 Paper 20671544 Paper 19725955 Paper 19638630 Paper 19601917 Paper 19380829 Paper 19201908 Paper 19110882 Paper 18572749 Paper 18032230 Paper 18000612 Paper 17707394 Paper 17566187 Paper 17417061 Paper 17286337 Paper 17196788 Paper 17167091 Paper 17087525 Paper 17085285 Paper 17072763 Paper 17069096 Paper 16824189 Paper 16764678 Paper 16704731 Paper 16540354 Paper 16472381 Paper 16447184 Paper 16440356 Paper 16420570 Paper 16274834 Paper 16249086 Paper 16210047 Paper 16152757 Paper 16099876 Paper 16086027 Paper 15993396 Paper 15957670 Paper 15885606 Paper 15869602 Paper 15857880 Paper 15845647 Paper 15820680 Paper 15809662 Paper 15809302 Paper 15797250 Paper 15737885 Paper 15722961 Paper 15717930 Paper 15699338 Paper 15596404 Paper 15582126 Paper 15564736 Paper 15563590 Paper 15545608 Paper 15538718 Paper 15528155 Paper 15520293 Paper 15476476 Paper 15466165 Paper 15461631 Paper 15456488 Paper 15447883 Paper 15389814 Paper 15378430 Paper 15324319 Paper 15322500 Paper 15316247 Paper 15307835 Paper 15274051 Paper 15258162 Paper 15254019 Paper 15246277 Paper 15229052 Paper 15226188 Paper 15225163 Paper 15223009 Paper 15220431 Paper 15192150 Paper 15181000 Paper 15178452 Paper 15163749 Paper 15158353 Paper 15158197 Paper 15146422 Paper 15123662 Paper 15123364 Paper 15100149 Paper 15054810 Paper 15031635 Paper 15008601 Paper 14982867 Paper 14726383 Paper 14714613 Paper 14660653 Paper 14636643 Paper 14633776 Paper 14613989 Paper 14607931 Paper 14572816

Abstract

The mode of entry of prostate specific antigen (PSA) and hK2 into the blood stream vary in benign versus malignant prostate disease. PSA and hK2 will be exposed to different spectra of complexing inhibitors and proteases. Thus assay of proportions of specific forms of PSA and hK2 in blood may have diagnostic and prognostic value greater than that of the total PSA test now used. We will collect serial samples from 300 patients with diagnosed prostate cancer (CaP) and correlate forms of hK2 and PSA to disease progression so that better treatment choices may be possible. We will collect serial samples from 300 patients about to undergo biopsy to correlate diagnosis to forms of hK2 and PSA and possibly allow many biopsies to be avoided. We will find if these markers predict who will develop CaP in the future.

View original record on NIH RePORTER →